{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T14:31:57Z","timestamp":1782397917201,"version":"3.54.5"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","trasci.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.transci.2016.09.003","type":"journal-article","created":{"date-parts":[[2016,9,13]],"date-time":"2016-09-13T16:38:34Z","timestamp":1473784714000},"page":"249-261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Anti-Xa bioassays for the laboratory measurement of direct Factor Xa inhibitors in plasma, in selected patients"],"prefix":"10.1016","volume":"55","author":[{"given":"Jean","family":"Amiral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Dunois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Amiral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerard","family":"Seghatchian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.transci.2016.09.003_bib0010","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/ATVBAHA.107.139402","article-title":"Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases","volume":"27","author":"Turpie","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.transci.2016.09.003_bib0015","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1365-2125.2007.02898.x","article-title":"Development of oral anticoagulants","volume":"64","author":"Ma","year":"2007","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.transci.2016.09.003_bib0020","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s11999-007-0092-4","article-title":"Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty","volume":"466","author":"Sharrock","year":"2008","journal-title":"Clin Orthop Relat Res"},{"issue":"6","key":"10.1016\/j.transci.2016.09.003_bib0025","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1538-7836.2008.02959.x","article-title":"An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage","volume":"6","author":"Poller","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"12","key":"10.1016\/j.transci.2016.09.003_bib0275","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jcin.2014.06.014","article-title":"Direct oral anticoagulants. New drugs and new concepts","volume":"7","author":"Levy","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"issue":"4","key":"10.1016\/j.transci.2016.09.003_bib0090","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1160\/TH13-09-0803","article-title":"New oral anticoagulant agents \u2013 general features and outcomes in subsets of patients","volume":"111","author":"Schulman","year":"2014","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.transci.2016.09.003_bib0030","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/europace\/eut083","article-title":"European Heart Rhythm Association. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation","volume":"15","author":"Heidbuchel","year":"2013","journal-title":"Europace"},{"issue":"10","key":"10.1016\/j.transci.2016.09.003_bib0035","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1177\/1060028014540868","article-title":"Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study","volume":"48","author":"Larock","year":"2014","journal-title":"Ann Pharmacother"},{"issue":"28","key":"10.1016\/j.transci.2016.09.003_bib0040","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1093\/eurheartj\/ehu027","article-title":"Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism","volume":"35","author":"Fontana","year":"2014","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.transci.2016.09.003_bib0045","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/europace\/euv309","article-title":"Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation","volume":"17","author":"Heidbuchel","year":"2015","journal-title":"Europace"},{"key":"10.1016\/j.transci.2016.09.003_bib0050","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2147\/TCRM.S72268","article-title":"Use of novel oral anticoagulants for the treatment of venous thromboembolism and its considerations in Asian patients","volume":"10","author":"Lee","year":"2014","journal-title":"Ther Clin Risk Manag"},{"issue":"10","key":"10.1016\/j.transci.2016.09.003_bib0055","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1253\/circj.CJ-14-0720","article-title":"Impact of non-vitamin K antagonist oral anticoagulants on intracranial bleeding in Asian patients with non-valvular atrial fibrillation","volume":"78","author":"Yasaka","year":"2014","journal-title":"Circ J"},{"issue":"4","key":"10.1016\/j.transci.2016.09.003_bib0060","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3109\/14756366.2010.535793","article-title":"Apixaban inhibition of factor Xa: microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma","volume":"26","author":"Luettgen","year":"2011","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"2","key":"10.1016\/j.transci.2016.09.003_bib0065","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1160\/TH10-02-0097","article-title":"Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin","volume":"104","author":"Wong","year":"2010","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.transci.2016.09.003_bib0070","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1161\/ATVBAHA.110.202978","article-title":"Rivaroxaban: a new oral factor Xa inhibitor","volume":"30","author":"Perzborn","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"23","key":"10.1016\/j.transci.2016.09.003_bib0075","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1093\/eurheartj\/ehv014","article-title":"Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation","volume":"36","author":"O'Donoghue","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.transci.2016.09.003_bib0080","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12959-015-0057-x","article-title":"Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V","volume":"13","author":"Fuji","year":"2015","journal-title":"Thromb J"},{"key":"10.1016\/j.transci.2016.09.003_bib0085","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/920361","article-title":"Update on edoxaban for the prevention and treatment of thromboembolism: clinical applications based on current evidence","volume":"2015","author":"Zalpour","year":"2015","journal-title":"Adv Hematol"},{"issue":"5","key":"10.1016\/j.transci.2016.09.003_bib0095","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1515\/CCLM.2011.134","article-title":"Laboratory assessment of new anticoagulants","volume":"49","author":"Samama","year":"2011","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"10.1016\/j.transci.2016.09.003_bib0100","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1515\/cclm-2014-0767","article-title":"Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?","volume":"53","author":"Lippi","year":"2015","journal-title":"Clin Chem Lab Med"},{"issue":"3","key":"10.1016\/j.transci.2016.09.003_bib0105","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/CIRCULATIONAHA.116.022307","article-title":"Urgent need to measure effects of direct oral anticoagulants","volume":"134","author":"Weitz","year":"2016","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.transci.2016.09.003_bib0110","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.thromres.2015.09.017","article-title":"The impact of oral anticoagulation on time to surgery in patients hospitalized with hip fracture","volume":"136","author":"Tran","year":"2015","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.transci.2016.09.003_bib0115","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1160\/TH12-03-0179","article-title":"Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers","volume":"108","author":"Marlu","year":"2012","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.transci.2016.09.003_bib0120","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.thromres.2014.07.036","article-title":"Ex vivo reversal of the anticoagulant effects of edoxaban","volume":"134","author":"Halim","year":"2014","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/j.transci.2016.09.003_bib0125","doi-asserted-by":"crossref","DOI":"10.1160\/TH16-05-0363","article-title":"Managing reversal of direct oral anticoagulants in emergency situations. Anticoagulation Education Task Force White Paper","volume":"116","author":"Ageno","year":"2016","journal-title":"Thromb Haemost"},{"issue":"10 Suppl. 2","key":"10.1016\/j.transci.2016.09.003_bib0130","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.2146\/ajhp150966","article-title":"Overview of direct oral anticoagulant therapy reversal","volume":"73","author":"Gulseth","year":"2016","journal-title":"Am J Health Syst Pharm"},{"issue":"10","key":"10.1016\/j.transci.2016.09.003_bib0135","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.annfar.2013.04.016","article-title":"Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) \u2013 March 2013","volume":"32","author":"Pernod","year":"2013","journal-title":"Ann Fr Anesth Reanim"},{"key":"10.1016\/j.transci.2016.09.003_bib0140","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/385014","article-title":"Management of non-vitamin K antagonist oral anticoagulants in the perioperative setting","volume":"2014","author":"Dincq","year":"2014","journal-title":"Biomed Res Int"},{"issue":"3","key":"10.1016\/j.transci.2016.09.003_bib0145","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.amj.2016.01.001","article-title":"Emergent bleeding in patients receiving direct oral anticoagulants","volume":"35","author":"Summers","year":"2016","journal-title":"Air Med J"},{"key":"10.1016\/j.transci.2016.09.003_bib0150","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1781684","article-title":"Direct-acting oral anticoagulants: practical considerations for emergency medicine physicians","volume":"2016","author":"Peacock","year":"2016","journal-title":"Emerg Med Int"},{"key":"10.1016\/j.transci.2016.09.003_bib0155","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4137\/CCRep.S27992","article-title":"Accidental rivaroxaban overdose in a patient with pulmonary embolism: some lessons for managing new oral anticoagulants","volume":"8","author":"Sajkov","year":"2015","journal-title":"Clin Med Insights Case Rep"},{"issue":"1","key":"10.1016\/j.transci.2016.09.003_bib0160","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pathol.2015.11.025","article-title":"The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples","volume":"48","author":"Bonar","year":"2016","journal-title":"Pathology"},{"issue":"1\u20132","key":"10.1016\/j.transci.2016.09.003_bib0165","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jchromb.2008.07.015","article-title":"Determination of rivaroxaban \u2013 a novel, oral, direct Factor Xa inhibitor \u2013 in human plasma by high-performance liquid chromatography-tandem mass spectrometry","volume":"872","author":"Rohde","year":"2008","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"1","key":"10.1016\/j.transci.2016.09.003_bib0170","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.thromres.2015.05.001","article-title":"Direct oral anticoagulants (DOACs) in the laboratory: 2015 review","volume":"136","author":"Adcock","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.transci.2016.09.003_bib0175","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.transci.2016.05.016","article-title":"An update on laboratory measurements of Dabigatran: smart specific and calibrated dedicated assays for measuring anti-Iia activity in plasma","volume":"54","author":"Amiral","year":"2016","journal-title":"Transfus Apher Sci"},{"issue":"1","key":"10.1016\/j.transci.2016.09.003_bib0180","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0272-2712(18)30346-9","article-title":"Laboratory monitoring of unfractionated heparin treatment","volume":"15","author":"Samama","year":"1995","journal-title":"Clin Lab Med"},{"issue":"1","key":"10.1016\/j.transci.2016.09.003_bib0185","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0272-2712(18)30347-0","article-title":"Contemporary laboratory monitoring of low molecular weight heparins","volume":"15","author":"Samama","year":"1995","journal-title":"Clin Lab Med"},{"issue":"5","key":"10.1016\/j.transci.2016.09.003_bib0190","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1160\/TH10-03-0204","article-title":"An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma","volume":"104","author":"Samama","year":"2010","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.transci.2016.09.003_bib0195","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1586\/ehm.13.11","article-title":"Monitoring plasma levels of factor Xa inhibitors: how, why and when?","volume":"6","author":"Samama","year":"2013","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"10.1016\/j.transci.2016.09.003_bib0200","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1055\/s-0038-1657886","article-title":"Questions and answers on prothrombin time standardisation in oral anticoagulant control","volume":"54","author":"Loeliger","year":"1985","journal-title":"Thromb Haemost"},{"issue":"5\u20136","key":"10.1016\/j.transci.2016.09.003_bib0205","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3109\/07853890.2013.801274","article-title":"Laboratory testing of rivaroxaban in routine clinical practice: when, how, and which assays","volume":"45","author":"Lindhoff-Last","year":"2013","journal-title":"Ann Med"},{"issue":"6","key":"10.1016\/j.transci.2016.09.003_bib0210","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/FTD.0b013e3181f2f264","article-title":"Assays for measuring rivaroxaban: their suitability and limitations","volume":"32","author":"Lindhoff-Last","year":"2010","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.transci.2016.09.003_bib0215","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1160\/TH13-06-0470","article-title":"Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study","volume":"111","author":"Gouin-Thibault","year":"2014","journal-title":"Thromb Haemost"},{"issue":"9","key":"10.1016\/j.transci.2016.09.003_bib0220","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00277-015-2407-y","article-title":"Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban","volume":"94","author":"K\u00f6nigsbr\u00fcgge","year":"2015","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.transci.2016.09.003_bib0225","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clpt.2005.06.011","article-title":"Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59\u20137939, an oral, direct factor Xa inhibitor","volume":"78","author":"Kubitza","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.transci.2016.09.003_bib0230","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1160\/TH13-04-0274","article-title":"Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS\/MS for the therapeutic monitoring of patients treated with rivaroxaban","volume":"110","author":"Douxfils","year":"2013","journal-title":"Thromb Haemost"},{"issue":"8","key":"10.1016\/j.transci.2016.09.003_bib0235","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1080\/15563650.2016.1187737","article-title":"Idarucizumab for dabigatran overdose","volume":"54","author":"Peetermans","year":"2016","journal-title":"Clin Toxicol (Phila)"},{"issue":"22","key":"10.1016\/j.transci.2016.09.003_bib0240","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1056\/NEJMc1411800","article-title":"Use of PER977 to reverse the anticoagulant effect of edoxaban","volume":"371","author":"Ansell","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2016.09.003_bib0245","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40164-015-0020-3","article-title":"Novel antidotes for target specific oral anticoagulants","volume":"4","author":"Das","year":"2015","journal-title":"Exp Hematol Oncol"},{"issue":"25","key":"10.1016\/j.transci.2016.09.003_bib0250","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet alfa for the reversal of Factor Xa inhibitor activity","volume":"373","author":"Siegal","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.transci.2016.09.003_bib0255","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1161\/ATVBAHA.114.303402","article-title":"Antidotes for novel oral anticoagulants: current status and future potential","volume":"35","author":"Crowther","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.transci.2016.09.003_bib0260","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.beha.2013.07.001","article-title":"Bleeding and antidotes in new oral anticoagulants","volume":"26","author":"Majeed","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"issue":"3","key":"10.1016\/j.transci.2016.09.003_bib0280","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/jth.12823","article-title":"Real-world variability in dabigatran levels in patients with atrial fibrillation","volume":"13","author":"Chan","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.transci.2016.09.003_bib0265","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.acvd.2014.04.007","article-title":"Comments on: laboratory tests for the management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants: proposals of the Working Group on Perioperative Haemostasis (GIHP): a rebuttal","volume":"107","author":"Pernod","year":"2014","journal-title":"Arch Cardiovasc Dis"},{"issue":"5","key":"10.1016\/j.transci.2016.09.003_bib0270","first-page":"525","article-title":"From old to new anticoagulants: the role of the biologist","volume":"67","author":"Samama","year":"2009","journal-title":"Ann Biol Clin (Paris)"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050216301112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050216301112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T00:37:14Z","timestamp":1601080634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050216301112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S1473050216301112"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2016.09.003","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-Xa bioassays for the laboratory measurement of direct Factor Xa inhibitors in plasma, in selected patients","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2016.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}